We’re in a global mental health crisis, and available psychiatric medicines fail to address the pressing unmet needs in patients.
Compounded by decades of stagnation, there is a dire need for new treatment options for those suffering from mental illness.
Our mission is to develop novel compounds that capture the therapeutic benefits of psychedelics to fundamentally reshape the treatment of mental illness.
Gilgamesh's AI-powered behavioral and imaging driven platform is accelerating and optimizing the development of our new chemical entities (NCEs) which offer improved safety, tolerability, duration, and efficacy.
We are a team of passionate neuroscience experts with decades of experience within large biopharma (Pfizer, Merck, Regeneron, Biogen, Lilly), exited startups (Perception Neuroscience, Kures, Springworks Therapeutics, Biohaven) and academia (Columbia University, Harvard University, NYU, Yale, UCSD).
Gilgamesh's discovery platform provides a state-of-the-art neurocircuitry-focused translational approach to novel drug candidate optimization and selection.
The platform aims to identify and classify novel psychoactive drugs by utilizing complex behavioral assessment, advanced electrophysiology and molecular measures of neuroplasticity.
This cutting edge approach incorporates machine learning algorithms to systematically characterize the multidimensional bioactivity of known and novel psychoactive molecules to improve clinical translation.